Technology

Antibody Platform

KisoJi‘s antibody platform was developed entirely in-house, leveraging decades of antibody discovery and development experience. This platform transforms how we think of antibody discovery, by systematically addressing multiple limitations of conventional antibody discovery technologies. By assembling a toolkit of capabilities spanning antibody generation, screening, lead selection and design, we are uniquely able to identify the full spectrum of antibody diversity, identify clusters with desired properties and optimize the construction and selection of lead candidates.

Our antibody platform includes multi-species single domain antibody transgenic mice, AI-enabled antibody fingerprinting for the best fit with specific epitopes on any target, and the ability to generate modular and easy-to-manufacture multi-specific antibodies.

KisoJi’s platform addresses key challenges in conventional antibody discovery processes, from initial antibody generation through to screening and lead selection/optimization. Our platform includes multi-species single domain antibody transgenic mice, AI-enabled antibody paratope fingerprinting and mapping for the best fit with specific epitopes on any target, and a toolkit to create robust, easily manufacturable multi-specific antibodies.

KisoMouse

The first transgenic mouse platform that provides the widest array of single domain antibodies of any animal.

KisoSeek

Structural antibody screening using next-generation sequencing and AI tools to guide antibody selection.

KisoBody

A powerfully simple, multi-functional and multi-specific antibody format designed to enhance efficacy and safety by targeting multiple antigens or epitopes simultaneously.

KisoJi's Advantages
Over Conventional Antibody Platforms

icon

Identify the full spectrum of antibody diversity

icon

Compare antibodies against an extensive antibody library

icon

Determine the comprehensiveness of the immune response across animals and across immunizations

icon

Make decisions based on directed sampling of the entire library

icon

Select antibodies by filtering clusters with the desired properties

icon

See the totality of the search space to understand what has been sampled and what remains unknown

Pipeline

From its platform, the KisoJi has developed a preclinical pipeline that includes tri-specific immuno-oncology antibodies for both solid and hematologic cancers, as well as a naked TROP2 antibody with significant single agent anti-tumor effects, including tumor regression, in solid tumor models without the need for a drug conjugate.

Drug Candidate Targets Format Development Stage Target Indications
KJ-101 PD1, CD47, D2 Tri-Specific Antibody IND-enabling Solid Tumors
KJ-102 PD1, CD47, CD36 Tri-Specific Antibody Research Acute Myeloid Leukemia
KJ-103 TROP2 Monoclonal Antibody IND-enabling Solid Tumors